Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Variables of Interest
2.3. Accuracy of the Therapeutic Ranges
2.4. Statistical Analysis
3. Results
3.1. Patients’ Demographic and Clinical Data
3.2. Response to Infliximab
3.3. Response to Adalimumab
3.4. Response to Etanercept
3.5. New Therapeutic Ranges
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Subedi, S.; Gong, Y.; Chen, Y.; Shi, Y. Infliximab and biosimilar infliximab in psoriasis: Efficacy, loss of efficacy, and adverse events. Drug Des. Dev. Ther. 2019, 13, 2491–2502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conejo-Mir, J.; Moreno, J.C.; Camacho, F.M. Manual de Dermatología; Aula Médica: Madrid, Spain, 2010. [Google Scholar]
- Ross, C.; Marsham, G.; Grillo, M.; Stanfort, T. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective. Aust. J. Dermatol. 2016, 57, 137–140. [Google Scholar] [CrossRef] [PubMed]
- Wang, T.C.; Chiu, H.Y.; Want, T.S.; Tsai, T.F. Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers. Dermatol. Sin. 2015, 33, 5–10. [Google Scholar] [CrossRef] [Green Version]
- Garces, S.; Demengeot, J.; Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. 2013, 72, 1947–1955. [Google Scholar] [CrossRef] [PubMed]
- Nanda, K.S.; Cheifetz, A.S.; Moss, A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis. Am. J. Gastroenterol. 2013, 108, 40–47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maneiro, J.R.; Salgado, E.; Gomez-Reino, J.J. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: Systematic review and meta-analysis. JAMA Intern. Med. 2013, 173, 1416–1428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mould, D.R. The pharmacokinetics of biologics: A primer. Dig. Dis. 2015, 33, 61–69. [Google Scholar] [CrossRef]
- Sbidian, E.; Chaimani, A.; Garcia-Doval, I.; Do, G.; Hua, C.; Mazaud, C.; Droitcourt, C.; Hughes, C.; Ingram, J.R.; Naldi, L.; et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst. Rev. 2017, 12, CD011535. [Google Scholar] [CrossRef]
- Sarzi-Puttini, P.; Ceribelli, A.; Marotto, D.; Batticciotto, A.; Atzeni, F. Systematic rheymatic diseases: From biological agents to small molecules. Auntoimmun. Rev. 2019, 18, 583–592. [Google Scholar] [CrossRef]
- Bartelds, G.M.; Wijbrandts, C.A.; Nurmohamed, M.T.; Stapel, S.; Lems, W.F.; Aarden, L.; Dijkmans, B.A.C.; Tak, P.P.; Wolbink, G.J. Clinical response to Adalimumab: Relationship to anti-adalimumab antibodies and serum Adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66, 921–926. [Google Scholar] [CrossRef]
- Valor, L.; De la Torre, I. Comprender el concepto de inmunogenicidad. Reumatol. Clin. 2013, 9, 1–76. [Google Scholar] [CrossRef] [PubMed]
- Syversen, S.W.; Goll, G.L.; Jørgensen, K.K.; Sandanger, Ø.; Sexton, J.; Olsen, I.C.; Gehin, J.E.; Warren, D.J.; Brun, M.K.; Klaasen, R.A.; et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA 2021, 325, 1744–1754. [Google Scholar] [CrossRef] [PubMed]
- Poulsen, A.S.K.; Thomsen, S.F.; Vinkel, C.; Ghazanfar, M.N.; Wulf-Johansson, H.; Bonne, R.; Larsen, R. Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis. Dermatol. Ther. 2020, 33, e13497. [Google Scholar] [CrossRef] [PubMed]
- Sbidian, E.; Chaimani, A.; Garcia-Doval, I.; Doney, L.; Dressler, C.; Hua, C.; Hughes, C.; Naldi, L.; Afach, S.; Le Cleach, L. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst. Rev. 2021, 4, CD011535. [Google Scholar] [CrossRef]
- Takahashi, H.; Tsuji, H.; Ishida-Yamamoto, A.; Iizuka, H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J. Dermatol. 2013, 40, 39–42. [Google Scholar] [CrossRef] [Green Version]
- Bito, T.; Nishikawa, R.; Hatakeyama, M.; Kikusawa, A.; Kanki, H.; Nagai, H.; Sarayama, Y.; Ikeda, T.; Yoshizaki, H.; Seto, H.; et al. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br. J. Dermatol. 2014, 170, 922–929. [Google Scholar] [CrossRef]
- Gottlieb, A.B.; Evans, R.; Li, S.; Dooley, L.T.; Guzzo, C.A.; Baker, D.; Bala, M.; Marano, C.W.; Menter, A. Infliximab induction therapy for patients with severe plaquetype psoriasis: A randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2004, 51, 534–542. [Google Scholar] [CrossRef]
- Krathen, R.A.; Berthelot, C.N.; Hsu, S. Sustained efficacy and safety of infliximab in psoriasis: A retrospective study of 73 patients. J. Drugs Dermatol. 2006, 5, 251–254. [Google Scholar]
- Gottlieb, A.B.; Kalb, R.E.; Blauvelt, A.; Heffernan, M.P.; Sofen, H.L.; Ferris, L.K.; Kerdel, F.A.; Calabro, S.; Wang, J.; Kerkmann, U.; et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study. J. Am. Acad. Dermatol. 2012, 67, 642–650. [Google Scholar] [CrossRef]
- Menter, A.; Feldman, S.R.; Weinstein, G.D.; Papp, K.; Evans, R.; Guzzo, C.; Li, S.; Dooley, L.T.; Arnold, C.; Gottlieb, A.B. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 2007, 56, e1–e15. [Google Scholar] [CrossRef]
- Liau, M.M.; Oon, H.H. Therapeutic drug monitoring of biologics in psoriasis. Biologics 2019, 13, 127–132. [Google Scholar] [CrossRef] [PubMed]
- Mahil, S.K.; Arkir, Z.; Richards, G.; Lewis, C.M.; Barker, J.N.; Smith, C.H. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: A singlecentre, cohort study. Br. J. Dermatol. 2013, 169, 306–313. [Google Scholar] [CrossRef] [PubMed]
- Papp, K.A.; Tyring, S.; Lahfa, M.; Prinz, J.; Griffiths, C.E.M.; Nakanishi, A.M.; Zitnik, R.; Van De Kerkhof, P.C.M.; the Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 2005, 152, 1304–1312. [Google Scholar] [CrossRef] [PubMed]
- Gordon, K.B.; Gottlieb, A.B.; Leonardi, C.L.; Elewski, B.E.; Wang, A.; Jahreis, A.; Zitnik, R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J. Dermatolog. Treat. 2006, 17, 9–17. [Google Scholar] [CrossRef] [PubMed]
- Tyring, S.; Gordon, K.B.; Poulin, Y.; Langley, R.G.; Gottlieb, A.B.; Dunn, M.; Jahreis, A. Long-term safety and efficacy of 50 mg of etanercept twice Weekly in patients with psoriasis. Arch. Dermatol. 2007, 143, 719–726. [Google Scholar] [CrossRef]
- Leonardi, C.; Strober, B.; Gottlieb, A.B.; Elewski, B.E.; Ortonne, J.P.; van de Kerkhof, P.; Chiou, C.F.; Dunn, M.; Jahreis, A. Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study. J. Drugs Dermatol. 2010, 9, 928–937. [Google Scholar]
- Lecluse, L.L.A.; Driessen, R.J.B.; Spuls, P.I.; de Jong, E.M.G.J.; Stapel, S.O.; van Doorn, M.B.A.; Jan, D.B.; Wolbink, G. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch. Dermatol. 2010, 146, 127–132. [Google Scholar] [CrossRef] [Green Version]
- Menter, A.; Tyring, S.K.; Gordon, K.; Kimball, A.B.; Leonardi, C.L.; Langley, R.G.; Strober, B.E.; Kaul, K.M.; Gu, Y.; Okun, M. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J. Am. Acad. Dermatol. 2008, 58, 106–115. [Google Scholar] [CrossRef]
- Menting, S.P.; Coussens, E.; Pouw, M.F.; van den Reek, J.M.; Temmerman, L.; Boonen, H.; de Jong, E.M.G.J.; Spuks, P.I.; Lambert, J. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: A step toward personalized treatment. JAMA Dermatol. 2015, 151, 616–622. [Google Scholar] [CrossRef] [Green Version]
- Reich, K.; Wozel, G.; Zheng, H.; Hoogstraten, H.J.F.; Flint, L.; Barker, J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: Results of a randomized, long-term extension trial (RESTORE2). Br. J. Dermatol. 2013, 168, 1325–1334. [Google Scholar] [CrossRef] [PubMed]
Drugs and Plasma Levels | PASI75 | No PASI75 | p Value | OR |
---|---|---|---|---|
Infliximab | ||||
Therapeutic | 8 | 0 | 0.01 | N/A * |
Subtherapeutic | 3 | 6 | <0.001 | N/A |
Supratherapeutic | 3 | 0 | 0.01 | N/A |
Adalimumab | ||||
Therapeutic | 17 | 0 | 0.005 | N/A |
Subtherapeutic | 18 | 10 | 0.005 | N/A |
Supratherapeutic | 0 | 0 | N/A | N/A |
Etanercept | ||||
Therapeutic | 23 | 16 | 0.01 | 0.29 (0.09–0.829) |
Subtherapeutic | 29 | 6 | 0.03 | 3.09 (1.05–9.10) |
Supratherapeutic | 2 | 0 | N/S * | N/A |
Drugs and Therapeutic Ranges | Patients Who Responded | |||
---|---|---|---|---|
with Established Ranges | with Proposed Ranges | |||
PASI75 | No PASI75 | PASI75 | No PASI75 | |
Infliximab | ||||
In range | 9 (45%) | 0 | 11 (55%) | 0 |
Out of range | 5 (25%) | 6 (30%) | 3 (15%) | 6 (30%) |
Adalimumab | ||||
In range | 17 (38%) | 2 (4%) | 26 (58%) | 4 (9%) |
Out of range | 18 (40%) | 8 (18%) | 9 (20%) | 6 (13%) |
Etanercept | ||||
In range | 23 (30%) | 16 (21%) | 49 (64%) | 19 (25%) |
Out of range | 31 (41%) | 6 (8%) | 5 (7%) | 3 (4%) |
Drugs and Parameters | Values | p Value | |
---|---|---|---|
with Established Ranges | with Proposed Ranges | ||
Infliximab | |||
Sensitivity | 64% | 78% | 0.02 |
Specificity | 100% | 100% | N/S * |
PPV | 100% | 100% | N/S |
NPV | 55% | 67% | N/S |
Adalimumab | |||
Sensitivity | 48% | 74% | <0.001 |
Specificity | 80% | 60% | N/S |
PPV | 89% | 87% | N/S |
NPV | 30% | 40% | N/S |
Etanercept | |||
Sensitivity | 59% | 72% | <0.0001 |
Specificity | 16% | 38% | N/S |
PPV | 46% | 91% | 0.008 |
NPV | 28% | 14% | N/S |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dodero-Anillo, J.M.; Lozano-Cuadra, I.C.; Rios-Sanchez, E.; Pedrosa-Martinez, M.J.; Ruiz-Carrascosa, J.C.; Galan-Gutierrez, M.; Armario-Hita, J.C. Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis. Life 2022, 12, 2075. https://doi.org/10.3390/life12122075
Dodero-Anillo JM, Lozano-Cuadra IC, Rios-Sanchez E, Pedrosa-Martinez MJ, Ruiz-Carrascosa JC, Galan-Gutierrez M, Armario-Hita JC. Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis. Life. 2022; 12(12):2075. https://doi.org/10.3390/life12122075
Chicago/Turabian StyleDodero-Anillo, Jose Manuel, Inmaculada Concepcion Lozano-Cuadra, Esmeralda Rios-Sanchez, Maria Jose Pedrosa-Martinez, Jose Carlos Ruiz-Carrascosa, Manuel Galan-Gutierrez, and Jose Carlos Armario-Hita. 2022. "Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis" Life 12, no. 12: 2075. https://doi.org/10.3390/life12122075